Navigation Links
WaferGen Reports Second Quarter 2011 Financial Results
Date:9/12/2011

Fee-for-Service.

Net Income/LossThe closing of the $30.6 million financing required a number of new accounting entries for the three and six months ended June 30, 2011 that resulted in non-cash charges to net income totaling $13.2 million, see details below.

For the second quarter ended June 30, 2011, net loss attributable to common stockholders is $18.6 million (of which $13.2 million is non-cash as above), or $(0.45) per share (basic and diluted), compared to a net income attributable to common stockholders of $646,000 or $0.02 per share (basic and diluted), for the same period in 2010. For the six months ended June 30, 2011, WaferGen reported a net loss attributable to common stockholders of $22.5 million (of which $13.2 million is non-cash as above), or $(0.54) per share (basic and diluted), compared to a net loss attributable to common stockholders of $3.9 million, or $(0.12) per share for the same period in 2010.

Of the $13.2 million non-cash charges for the three and six months ended June 30, 2011, $9.3 million is a one-time accretion expense related to a beneficial conversion feature arising on issuance of the Series A-1 convertible preferred stock; $2.3 million is a one-time interest expense arising from the issuance of convertible promissory notes, and $1.6 million is a non-cash expense on the revaluation of the conversion element of the convertible promissory notes, that can fluctuate in future periods based on the company's stock price.

Net loss for the three and six months ended June 30, 2011 was also impacted by warrant derivative revaluations.  Net loss from warrant derivative revaluations for the three months ended June 30, 2011 was $191,000, compared to net gain of $3.6 million for the three months ended June 30, 2010; and net gain of $300,000 for the six months ended June 30, 2011 compared to net gain of $1.7 million for the six months ended June 30, 2010.  These non-cash gains and losses are attributed to r
'/>"/>

SOURCE WaferGen Biosystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. WaferGen to Present at OneMedForum New York 2011
2. WaferGen Closes $30 Million Financing with Three Leading Life Science Institutional Investors
3. WaferGen Announces Data Presentations From Newly Launched High-Throughput SmartChip Human microRNA Panel V2 at Scientific Conferences, Including AACR
4. WaferGen Launches High-Throughput SmartChip Human MicroRNA Panel V2
5. WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results
6. WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors
7. WaferGen to Present at 13th Annual BIO CEO and Investor Conference
8. WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
9. WaferGen to Present at OneMedForum San Francisco 2011
10. WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System
11. WaferGen Announces $7 Million Capital Raise -- $5 Million Equity Private Placement Agreement Signed, and $2 Million Credit Facility Closed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 Huntington Memorial ... Valley to perform transcatheter aortic valve replacement (TAVR), a ... is a revolutionary new way to replace an aortic ... a heart lung machine. The procedure is ... led by Azhil ( Alex) Durairaj , MD, interventional ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
(Date:3/26/2015)... 26, 2015 According to a ... Volume, Technology (RF, Microwave, Cryoablation, Others), Department (Interventional Radiology, ... Bone Metastasis) - Global Forecasts to 2019", published by ... around $462.0 Million growing at a CAGR of 11.50% ... and 57 figures spread through 195 pages and in-depth ...
Breaking Medicine Technology:Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Tumor Ablation Market Worth $462.0 Million by 2019 2Tumor Ablation Market Worth $462.0 Million by 2019 3Tumor Ablation Market Worth $462.0 Million by 2019 4
... CHAPEL HILL, N.C., May 23 With increased ... generics in the,pharmaceutical market, marketing teams and science ... clinical trial results of new drugs in,development. With ... ones that do have to be spot on ...
... Coalition of Cancer Cooperative Groups sheds light on the ... on Grey,s Anatomy are not just ,do or die., ... episodes and,two-hour season finale of "Grey,s Anatomy" centered on ... doctors, the subject tops the,list of the country,s healthcare ...
Cached Medicine Technology:New Pharma Business Model Increases Pressure on Staff Communicating Trial Data 2The 'Anatomy' of Clinical Trials: 'Grey's' Season Finale Leaves Public in the Dark About the Myths and Realities 2The 'Anatomy' of Clinical Trials: 'Grey's' Season Finale Leaves Public in the Dark About the Myths and Realities 3
(Date:3/27/2015)... 2015 The 2015 Deep Market ... professional and in-depth study on the current state ... a focus on the Chinese situation. , The ... including definitions, classifications, applications and industry chain structure. ... the international and Chinese domestic situations including development ...
(Date:3/27/2015)... March 27, 2015 Airy Jeanine is ... the official music video for her debut song “Mama’s ... Combining live-action and abstract styling effects, the thematic video ... on YouTube, Vimeo, and assorted outlets. It will be ... of an expanding full-scale marketing strategy. The video promotion ...
(Date:3/27/2015)... 27, 2015 Smile Brands Inc. ( ... business support services to dental groups in the United ... affiliated Castle Dental office in Hendersonville, TN. ... 37075, this new Castle Dental office provides families with ... latest in comprehensive, quality dental care. Hendersonville marks the ...
(Date:3/27/2015)... “ VXi BlueParott Reveal ” was ... Report, which features the latest and coolest technology products ... special reporter for NewsWatch, conducted the review and shared ... eliminating 90% of ambient noise. , Today, business is ... are important to any professional, voice calls are just ...
(Date:3/27/2015)... March 27, 2015 The Florida Center ... Brain Cancer Cure (ABC2), awarded $350,000 to support brain ... Florida, The Scripps Research Institute and H. Lee Moffitt ... studies with a clear development path and potential to ... the near future. , The awards fund research ...
Breaking Medicine News(10 mins):Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3Health News:Airy Jeanine Releases ‘’Mama’s Girl” Official Music Video 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 3Health News:A Device to Tune out Background Noise was Recently Featured on NewsWatch Television 2Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 2Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 3
... , , , ... 100 mg showed clear advantages over Crinone* (progesterone gel) for ... (PK) study. Progesterone is necessary to increase endometrial receptivity ... , , ENDOMETRIN(R) rapidly reached ...
... , , CHICAGO, Aug. ... ADLS), today announced positive results from an animal study involving ... to measure Restanza,s therapeutic efficacy in treating inhalation anthrax after ... non-human primate study showed that a 14-day course of Restanza ...
... , FRANKLIN, Mass., Aug. 31 PLC Systems Inc. ... vascular medical device-based technologies, today announced that it will demonstrate its ... European Society of Cardiology, August 29 - September 2, 2009 in ... to attend this event. , , ...
... , OAKLAND, Calif., Aug. 31 Life ... that keep mind, body and emotions rigid. Especially during stressful ... is a challenge. The Breema Bodywork Method helps people find ... regardless of what challenges they may be facing. To help ...
... BEIJING, Aug. 31 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:, ... China, announced,today that Sinovac,s H1N1 vaccine has passed the experts ... vaccine is expected to,obtain the production license within this week. ... 2009, State Food and Drug Administration (SFDA),organized and held an ...
... , DEERFIELD, Ill., Aug. 31 Chicago-based Lundbeck ... Achievement by the Illinois Chapter of the Huntington,s Disease Society of ... (HD) community and making a meaningful contribution to the lives of ... past Friday at the fifth annual Celebration of Hope ...
Cached Medicine News:Health News:Recently Published Study Demonstrates Pharmacokinetic Advantages of ENDOMETRIN(R) Over Crinone(R) for Progesterone Supplementation 2Health News:Recently Published Study Demonstrates Pharmacokinetic Advantages of ENDOMETRIN(R) Over Crinone(R) for Progesterone Supplementation 3Health News:Advanced Life Sciences' Restanza Demonstrates Efficacy in Treating Anthrax Infection 2Health News:Advanced Life Sciences' Restanza Demonstrates Efficacy in Treating Anthrax Infection 3Health News:Advanced Life Sciences' Restanza Demonstrates Efficacy in Treating Anthrax Infection 4Health News:Advanced Life Sciences' Restanza Demonstrates Efficacy in Treating Anthrax Infection 5Health News:PLC Medical Systems to Demonstrate RenalGuard(R) at ESC 2009 2Health News:PLC Medical Systems to Demonstrate RenalGuard(R) at ESC 2009 3Health News:PLC Medical Systems to Demonstrate RenalGuard(R) at ESC 2009 4Health News:The Breema Center Presents Its Fall Week-Long Intensive on Giving and Receiving Breema Bodywork 2Health News:Sinovac's H1N1 Vaccine Passes Experts Evaluation Organized by SFDA 2Health News:Sinovac's H1N1 Vaccine Passes Experts Evaluation Organized by SFDA 3Health News:Lundbeck Inc. Recognized With Award of Excellence in Corporate Achievement for Its Commitment to Huntington's Disease Community 2Health News:Lundbeck Inc. Recognized With Award of Excellence in Corporate Achievement for Its Commitment to Huntington's Disease Community 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: